+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the ALPCO Calprotectin CLIA test, an in vitro diagnostic tool that measures calprotectin protein levels in stool samples. Calprotectin is a marker of inflammation in the gut, which helps distinguish Inflammatory Bowel Disease IBD, including Crohns Disease and Ulcerative Colitis, from Irritable Bowel Syndrome IBS. The studys purpose is to confirm how well this test predicts positive and negative results in patients showing symptoms of IBS or IBD. Participants include adults with suspected IBD or IBS who provide stool samples for calprotectin measurement before or shortly after colonoscopy. The study will compare calprotectin levels measured by the ALPCO test with diagnoses confirmed through colonoscopy and histology. The test uses proposed cut-off values such as 50 gg to indicate inflammation presence, guiding whether further invasive testing is needed. During the study, patients will provide stool samples and undergo colonoscopy or have recent colonoscopy results reviewed. Samples will be frozen and later tested to measure calprotectin levels. Researchers will analyze the agreement between the test results and clinical diagnosis to assess the tests sensitivity and specificity. The primary outcome is the diagnostic value of calprotectin measurement, tracked up to 52 weeks, with participation lasting until study completion around the end of 2026.

Age: 22Years +All Genders
3 locations